Lexaria Bioscience Corp.
LEXX- Exchange
- Nasdaq
- Industry
- Pharmaceutical Preparations
- SEC CIK
- 0001348362
No open-market purchases or sales by Lexaria Bioscience Corp. insiders were filed in the last 90 days; 31 institutions reported holding it in 13F filings for Q2 2026, worth $920.0K in total; no superinvestor holds it.
13F holders, Q2 2023
Institutional positions in Lexaria Bioscience Corp. as of Jun 30, 2023. Investment managers with $100 million or more in US stocks report their long positions on Form 13F within 45 days after each quarter ends. How 13F works
- Institutional holders
- 14
- −3 vs. Q1 2023
- Shares held
- 892.7K
- +213.5K (+31.4%) vs. Q1 2023
- Total value
- $651.4K
- −$1.20M (−64.7%) vs. Q1 2023
- New holders
- 0
- 3 more added
- Sold out
- 3
- 3 more reduced
Compare with Q1 2023: new holders, sold out and not filed yet
Holders and value by quarter
Institutions reporting LEXX on Form 13F each quarter since Q1 2021, and the total value they reported. Values are as of each quarter end, so they also move with the share price.
| Quarter | Holders | Value |
|---|---|---|
| Q2 2026 | 31 | $920.0K |
| Q1 2026 | 28 | $1.17M |
| Q4 2025 | 21 | $1.05M |
| Q3 2025 | 25 | $1.63M |
| Q2 2025 | 21 | $2.00M |
| Q1 2025 | 22 | $2.12M |
| Q4 2024 | 25 | $3.03M |
| Q3 2024 | 27 | $3.25M |
| Q2 2024 | 28 | $5.72M |
| Q1 2024 | 25 | $3.23M |
| Q4 2023 | 20 | $1.49M |
| Q3 2023 | 15 | $1.77M |
| Q2 2023 | 14 | $651.4K |
| Q1 2023 | 17 | $1.85M |
| Q4 2022 | 16 | $1.71M |
| Q3 2022 | 16 | $1.68M |
| Q2 2022 | 16 | $1.67M |
| Q1 2022 | 12 | $1.41M |
| Q4 2021 | 13 | $1.85M |
| Q3 2021 | 11 | $2.83M |
| Q2 2021 | 10 | $2.93M |
| Q1 2021 | 9 | $1.78M |
Institutions, Q2 2023
Shares, value and share of portfolio for each institution holding Lexaria Bioscience Corp.; share changes are against Q1 2023.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| Royal Bank of Canada | 394 | $0 | 0.00% | 00.0% | Unchanged |
| Toronto Dominion Bank | 13 | $0 | 0.00% | 00.0% | Unchanged |
| UBS Group AG | 99 | $72 | 0.00% | −4,540−97.9% | Reduced |
| Farther Finance Advisors, LLC | 166 | $121 | 0.00% | 00.0% | Unchanged |
| Aspire Private Capital, LLC | 400 | $292 | 0.00% | 00.0% | Unchanged |
| Wells Fargo & Company | 1,071 | $782 | 0.00% | +2+0.2% | Added |
| Advisor Group Holdings, Inc. | 2,043 | $1.49K | 0.00% | 00.0% | Unchanged |
| 1832 Asset Management L.P. | 2,686 | $1.96K | 0.00% | 00.0% | Unchanged |
| Tower Research Capital LLC (TRC) | 10,951 | $7.99K | 0.00% | +6,862+167.8% | Added |
| Renaissance Technologies LLC | 10,700 | $8.00K | 0.00% | −2,900−21.3% | Reduced |
| Susquehanna International Group, LLP | 15,426 | $11.2K | 0.00% | −52,026−77.1% | Reduced |
| Vanguard Group Inc | 33,329 | $24.3K | 0.00% | 00.0% | Unchanged |
| Geode Capital Management, LLC | 48,837 | $35.3K | 0.00% | 00.0% | Unchanged |
| Invenomic Capital Management LP | 766,573 | $559.8K | 0.03% | +293,470+62.0% | Added |
| Dimensional Fund Advisors LP | 0 | $0 | 0.00% | −15,268−100.0% | Sold out |
| Centiva Capital, LP | 0 | $0 | 0.00% | −12,059−100.0% | Sold out |
| Gables Capital Management Inc. | 0 | $0 | 0.00% | −13−100.0% | Sold out |